Liste des Actualités Cancer du Sein

jeudi 24 mai 2007 Ipsogen is part of COBRED, a breast & colon cancer biomarker European project.

Marseille, France, May 24, 2007 – IPSOGEN today announced that COBRED project coordinated by BioSystems International (Paris) has been awarded a 2.9 M€ grant as part of the 6th Framework Programme.

COBRED project aims at...

Categorie: Cancer du sein

jeudi 24 mai 2007 Ipsogen part of a 2.9 M€ granted European project dedicated to breast and colon cancer biomarker research - ‘COBRED project’

IPSOGEN today announced that COBRED project coordinated by BioSystems International (Paris) has been awarded a 2.9 M€ grant as part of the 6th Framework Programme.COBRED project aims at discovering breast cancer (BC) and colon...

Categorie: Cancer du sein

mercredi 13 décembre 2006 Ipsogen and anti cancer centres to initiate a prospective clinical trial for use of a genomic signature for managing chemotherapeutic options in breast cancer

Marseille, France, December 13, 2006

Read more

– Ipsogen SAS, a French biotechnology company and a group of comprehensive cancer centres led by Institut Paoli-Calmettes (IPC) today announced that the clinical trial SA02 is...

Categorie: Cancer du sein

vendredi 24 février 2006 Ipsogen presents breast cancer biomarker results at the upcoming EBCC 5, the 5th European Breast Cancer Conference

Marseille, France, February 24, 2005 – Ipsogen SAS, the French cancer diagnostics company, announced today that its latest breast cancer program results had been selected for presentation at the EBCC 5 congress, the 5th European...

Categorie: Cancer du sein

jeudi 13 octobre 2005 Ipsogen presents breast cancer biomarker results at the European Cancer Conference ECCO 13

Marseille, France, October 13, 2005 –

The abstract titled "Utilisation of microarray technology to refine molecular classes and improve clinical management of breast cancer," has been selected by the ECCO 13...

Categorie: Cancer du sein

mercredi 30 mars 2005 Ipsogen to present breast cancer program results at the upcoming AACR annual meeting.

Marseille, France, March 30, 2005 –

The abstract titled "Utilisation of microarray technology to refine molecular classes and improve clinical management of breast cancer," is available on the AACR website (

Read...

Categorie: Cancer du sein

mercredi 27 octobre 2004 Ipsogen signs an agreement with the Cleveland Clinic to identify molecular markers in early stage breast cancer.

Marseille, France, Wednesday, 27 October 2004 - Ipsogen announced today that it has signed an agreement with The Cleveland Clinic and Dr. Richard Crownover (Cleveland, USA) to identify molecular markers in early stage breast...

Categorie: Cancer du sein

vendredi 23 juillet 2004 Ipsogen signs an agreement to become an authorised service provider for Affymetrix technologies

“Adding the AFFYMETRIX Platform to our technology portfolio strengthens our ability to meet the needs of our academic and industry partners to optimize drug development and personalise patient care in oncology. GeneChip®...

Categorie: Cancer du sein

jeudi 06 mai 2004 Ipsogen announces selection by the French network of anti-cancer centres to investigate gene expression in breast tumours treated with anthracycline therapy.

“This agreement with FNCLCC is an important critical step in applying genomic tools to improve standard chemotherapy regimen in breast cancer. This large scale genomic study will provide homogeneous treatments and monitoring...

Categorie: Cancer du sein

lundi 15 avril 2002 Ipsogen announces the publication of results on a new breast cancer profiling study.

Marseille, France, April 15th, 2002 – Ipsogen today announced results of a study which were obtained in close collaboration with the company’s clinical partner, the Institut Paoli-Calmettes, a major French anti-cancer centre. The...

Categorie: Cancer du sein